The Conversation (0)
Ischemix Inc., a biotechnology company that develops cytoprotective compounds to treat advanced renal and cardiovascular conditions, made an announcement today that it has appointed David A. DeWahl, Jr. as its new President and CEO.
Ischemix Inc., a biotechnology company that develops cytoprotective compounds to treat advanced renal and cardiovascular conditions, made an announcement today that it has appointed David A. DeWahl, Jr. as its new President and CEO.
As quoted in the press release:
“We are extremely pleased to welcome Mr. DeWahl as our CEO. His background in building life sciences companies and his experience in developing corporate collaborations in the industry and in raising capital will substantially strengthen Ischemix as we continue the clinical development of our drug candidates,” said Reinier Beeuwkes, Ph.D., Chairman of the Board and Chief Scientific Officer of the Company.